Abstract 282P
Background
Metabolic syndrome clusters obesity, hypertension, hyperglycemia, high triglycerides, and low high-density lipoprotein (HDL). These metabolic factors are individual risk factors for cardiovascular diseases, and suggestively impaired breast cancer (BC) prognosis. This systematic review and meta-analysis evaluates the impact of metabolic syndrome on disease-free survival in BC survivors.
Methods
Systematic searches were conducted in PubMed and Embase using variations of the search terms breast neoplasms (population), metabolic syndrome (exposure), and survival (outcome). Metabolic syndrome was defined according to the American Heart Association and includes presence of three out of five abnormal findings among the following risk factors: elevated blood pressure, elevated triglycerides, reduced HDL, elevated fasting glucose, and central obesity. Data were extracted from observational studies and randomized controlled trials, which used survival statistics and reported ratios of survival, e.g. hazard ratios (HRs) or survival curves to examine how the presence of metabolic syndrome at the time of diagnosis of BC impacts disease-free survival. Guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), study data were extracted independently by two authors. The effect sizes were combined with random-effects models.
Results
From the 953 studies identified in the literature search, the study selection process found 18 eligible studies, which included 36, 822 BC survivors. The pooled estimates show that breast cancer survivors with metabolic syndrome at BC diagnosis had shorter disease-free survival in comparison with BC survivors without metabolic syndrome (HR 1.22 95% CI: 1.10 – 1.33).
Conclusions
Among BC survivors, metabolic syndrome was associated with shorter disease-free survival. This warrants development of clinical guidelines including metabolic screening of BC survivors, and further research to determine interventions, which reduce the prevalence of metabolic syndrome among BC survivors towards improved survival.
Legal entity responsible for the study
S. Harborg.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.